Hypothesis
Senescent endothelial and smooth‑muscle cells in the aging vasculature do not merely drive pathology; they also secrete a SASP‑enriched TGF‑β1/Peptide cocktail that keeps resident progenitor cells in a quiescent, reparative state. When senolytics abolish this signaling niche, progenitor cells proliferate unchecked, depositing excess collagen and elastin fragments that stiffen the artery wall. Thus, the net effect of senolysis depends on the balance between SASP‑mediated progenitor restraint and the intrinsic pro‑fibrotic drive of those progenitors. Supplementing TGF‑β1 (or mimicking its downstream Smad2/3 signaling) during senolytic treatment should preserve the protective restraint while clearing the damaging SASP components, preventing the fibrosis‑induced rise in arterial stiffness.
Mechanistic Rationale
- SASP composition matters – While IL‑6, TNF‑α, and MMPs dominate the deleterious SASP, recent proteomics of senescent vascular cells show a concurrent rise in latent TGF‑β1 and its activators (e.g., thrombospondin‑1) [1 [2]. TGF‑β1 is a potent inhibitor of endothelial‑to‑mesenchymal transition (EndMT) and suppresses collagen‑I transcription in adventitial fibroblasts via Smad7 feedback.
- Progenitor cell niche – The vasculature harbors Sca‑1⁺/CD34⁺ resident progenitors that contribute to neointimal formation after injury. In vitro, TGF‑β1 blocks their proliferation and shifts them toward a contractile phenotype (α‑SMA⁺) [[3](https://pmc





























